MAPK3 and neoplasm: Additionally, the results showing that AMG386 reduces p‐ERK1/2 and activates STAT3 in tumor endothelial cells are consistent with the reduced activity of EphrinB in tumor endothelial cells of mice treated with AMG386 (Fig 6C).